Anna Hedberg
5 IP cases indexed. Covers patent matters.
Cases Presided Over
5 cases indexed | Page 1 of 1
Merz Pharmaceuticals LLC v.Viatris Santé
This UPC Court of Appeal decision clarifies the strict procedural requirements for maintaining confidentiality in proceedings. The court ruled that merely requesting confidentiality under R. 262.2 RoP is insufficient to restrict disclosure by opposing parties; a formal application under R. 262A RoP must be made simultaneously with lodging confidential evidence. This ruling emphasizes that unrestricted access is the default, and procedural compliance is mandatory for any restriction.
Syngenta Limited v.Sumi Agro Europe Limited
In a significant ruling on provisional measures, the UPC Court of Appeal affirmed the validity and infringement likelihood of EP 2 152 073 concerning herbicide compositions. The court confirmed that the balance of interests favored granting an injunction against Sumi Agro. Furthermore, it clarified procedural aspects, specifically rejecting the requirement for Syngenta to provide security for enforcement, which is a key relief for patent holders seeking immediate protection.
Alexion Pharmaceuticals, Inc. v.Samsung Bioepis NL B.V.
This UPC Court of Appeal decision addressed an application for provisional measures concerning a C5-binding antibody patent. The core issue revolved around claim interpretation, specifically whether a sequence ID number included extra amino acids as interpreted by the Technical Board of Appeal (TBA). The court ultimately found that this interpretation led to insufficient disclosure under Art. 83 EPC because the resulting claimed molecule was not functional as intended for drug use. Alexion's appeal was rejected, reinforcing strict standards regarding claim scope and enablement in biotech patents.
Alexion Pharmaceuticals, Inc. v.Amgen Technology (Ireland) Unlimited Company et al.
This UPC Court of Appeal decision addressed an application for provisional measures concerning a monoclonal antibody used to treat rare diseases like PNH. The core dispute revolved around the interpretation and validity of the patent claims, specifically regarding amino acid sequences. The court ruled that the claim was insufficiently disclosed because the full sequence did not possess the claimed therapeutic activity, leading to the rejection of Alexion's appeal.
Sumi Agro Limited v.Syngenta Limited
This UPC Court of Appeal decision addressed procedural issues arising from an appeal challenging provisional measures against Sumi Agro Limited. The core dispute involved the alleged infringement by Syngenta using different versions of a product named 'Kagura' (2023 vs 2024). The court ultimately allowed Syngenta to introduce new evidence detailing the characteristics and purchase of the 2024 product, finding that the late submission was justified. This ruling highlights the UPC's flexibility in allowing relevant factual developments during appeal proceedings.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.